L
Lotta Hansson
Researcher at Karolinska Institutet
Publications - 75
Citations - 1932
Lotta Hansson is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Chronic lymphocytic leukemia & Medicine. The author has an hindex of 20, co-authored 57 publications receiving 1176 citations. Previous affiliations of Lotta Hansson include Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
Yutai Gao,Curtis Cai,Alba Grifoni,Thomas R. Müller,Julia Niessl,Anna Olofsson,Marion Humbert,Lotta Hansson,Anders Österborg,Peter Bergman,Puran Chen,Annika Olsson,Johan Sundberg,Daniela Weiskopf,David Price,Hans-Gustaf Ljunggren,Annika C. Karlsson,Alessandro Sette,Soo Aleman,Marcus Buggert +19 more
TL;DR: In this article , the authors report that SARS-CoV-2 spike-specific CD4+ and CD8+ T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against B.1.529.
Journal ArticleDOI
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Peter Bergman,Peter Bergman,Ola Blennow,Ola Blennow,Lotta Hansson,Lotta Hansson,Stephan Mielke,Stephan Mielke,Piotr Nowak,Piotr Nowak,Piotr Nowak,Puran Chen,Gunnar Söderdahl,Gunnar Söderdahl,Anders Österborg,Anders Österborg,C. I. Edvard Smith,David J. Wullimann,Jan Vesterbacka,Gustaf Lindgren,Lisa Blixt,Lisa Blixt,Gustav Friman,Gustav Friman,Emilie Wahren Borgström,Anna Nordlander,Angelica Cuapio Gomez,Mira Akber,Davide Valentini,Anna-Carin Norlin,Anders Thalme,Gordana Bogdanovic,Sandra Muschiol,Sandra Muschiol,Peter Nilsson,Sophia Hober,Karin Loré,Margaret Chen,Marcus Buggert,Hans-Gustav Ljunggren,Per Ljungman,Per Ljungman,Soo Aleman,Soo Aleman +43 more
TL;DR: In this paper, the authors investigated safety and efficacy of BNT162b2 mRNA vaccination in five selected groups of immunocompromised patients and healthy controls and found that the vaccine was safe.
Journal ArticleDOI
Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML
Andreas T. Björklund,Mattias Carlsten,Ebba Sohlberg,Lisa L. Liu,Trevor Clancy,Trevor Clancy,Mohsen Karimi,Sarah Cooley,Jeffrey S. Miller,Monika Klimkowska,Marie Schaffer,Emma Watz,Kristina I. Wikstrom,Pontus Blomberg,Pontus Blomberg,Björn E. Wahlin,Marzia Palma,Lotta Hansson,Per Ljungman,Eva Hellström-Lindberg,Hans-Gustaf Ljunggren,Karl-Johan Malmberg +21 more
TL;DR: This study suggests that high-risk MDS is responsive toNK-cell therapy and supports the use of haploidentical NK-cell infusions as a bridge to HSCT in refractory patients.
Journal ArticleDOI
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
Marzia Palma,Giusy Gentilcore,Kia Heimersson,Fariba Mozaffari,Barbro Näsman-Glaser,Emma Young,Richard Rosenquist,Lotta Hansson,Lotta Hansson,Anders Österborg,Anders Österborg,Håkan Mellstedt +11 more
TL;DR: In conclusion, chronic lymphocytic leukemia T cells display increased expression of immune checkpoints, abnormal subset distribution, and a higher proportion of proliferating cells compared to healthy T cells.
Journal ArticleDOI
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Maria Winqvist,Anna Asklid,Per Andersson,Karin Karlsson,Claes Karlsson,Claes Karlsson,Birgitta Lauri,Jeanette Lundin,Jeanette Lundin,Mattias Mattsson,Stefan Norin,Anna Sandstedt,Lotta Hansson,Anders Österborg,Anders Österborg +14 more
TL;DR: Real-world analysis on consecutive chronic lymphocytic leukemia patients from a well-defined geographical region shows the efficacy and safety of ibrutinib to be similar to that of pivotal trials, yet, del(17p)/TP53 mutation remains a therapeutic challenge.